The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross‐national comparison study

医学 中国 药品审批 肿瘤科 环境卫生 药理学 政治学 药品 法学
作者
Jian Yan,Hongtao Li,Pei Zhang,Man Yu,Huan Zhang,Xin Li
出处
期刊:International Journal of Cancer [Wiley]
卷期号:152 (11): 2351-2361 被引量:4
标识
DOI:10.1002/ijc.34427
摘要

Immune checkpoint inhibitors (ICIs) are currently one of the most popular treatment methods for cancers. Several ICIs have been approved in China and the United States. We created a database of approved ICIs by extracting the information of interest from the drug labels and reviewing documents disclosed on the official websites of the US Food and Drug Administration (FDA) and the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) and compared the difference between the marketed ICIs in China and the United States regarding the number of indications, tumor types, review time, treatment setting, and so forth. Until June 30, 2022, 9 and 15 ICIs had been approved for 86 and 58 indications in the United States and China, involving 20 and 14 types of tumors, respectively. The correlation between indications and disease incidence was higher in China (r = 0.64) than in the United States (r = 0.45). About half of the indications were approved as first-line therapies in combination with chemotherapy, target therapy, or immunotherapy. Over 30% of indications were approved under accelerated or conditional approval in the two countries. A shorter regulatory review time was required by the FDA (median:181 days) compared to the NMPA (median: 279 days) for the new indication approval. Five ICIs marketed in China were approved by the FDA before the NMPA, with the median launch delay for the same indication of 344 days in China. A differentiated clinical development program that focuses on meeting unmet needs may bring new success for subsequent ICI products.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
正直冰露完成签到,获得积分10
刚刚
tiger发布了新的文献求助10
刚刚
1秒前
plummin发布了新的文献求助10
1秒前
2秒前
吃猫的鱼发布了新的文献求助10
2秒前
2秒前
无奈若雁完成签到,获得积分10
2秒前
3秒前
一一应助Liang采纳,获得10
3秒前
3秒前
3秒前
科研小狗完成签到,获得积分10
4秒前
5秒前
5秒前
zhenxing发布了新的文献求助10
5秒前
5秒前
6秒前
7秒前
hyl发布了新的文献求助10
7秒前
ygr应助南北采纳,获得20
7秒前
fribbleeee发布了新的文献求助10
8秒前
烟花应助落后的书白采纳,获得10
8秒前
安静黄豆发布了新的文献求助10
8秒前
8秒前
卬卯卯完成签到,获得积分10
8秒前
8秒前
西早完成签到 ,获得积分10
9秒前
9秒前
9秒前
hhjndjnjk完成签到,获得积分10
10秒前
Jennywrz发布了新的文献求助10
10秒前
岁月如歌发布了新的文献求助30
11秒前
11秒前
五五乐发布了新的文献求助10
11秒前
liyanglin完成签到 ,获得积分10
11秒前
风信子完成签到,获得积分10
11秒前
zyd完成签到 ,获得积分10
11秒前
12秒前
李大白发布了新的文献求助10
12秒前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3068620
求助须知:如何正确求助?哪些是违规求助? 2722514
关于积分的说明 7477972
捐赠科研通 2369607
什么是DOI,文献DOI怎么找? 1256459
科研通“疑难数据库(出版商)”最低求助积分说明 609594
版权声明 596839